Efficacy and safety of Albuvirtide plus Lopinavir-ritonavir in HIV-1-infected adults failed standard first-line ART regimen

Trial Profile

Efficacy and safety of Albuvirtide plus Lopinavir-ritonavir in HIV-1-infected adults failed standard first-line ART regimen

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Albuvirtide (Primary) ; Lamivudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TALENT
  • Sponsors Frontier Biotechnologies
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Aug 2016 Status changed from recruiting to completed.
    • 06 Jun 2016 According to Frontier Biotechnologies media release, and NDA is to be submitted to China FDA in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top